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Abstract Despite the fact that colorectal cancer (CRC) is
a highly treatable form of cancer if detected early, a very
low proportion of the eligible population undergoes
screening for this form of cancer. Integrating a genomic
screening proﬁle as a component of existing screening
programs for CRC could potentially improve the effec-
tiveness of population screening by allowing the assign-
ment of individuals to different types and intensities of
screening and also by potentially increasing the uptake of
existing screening programs. We evaluated the utility and
predictive value of genomic proﬁling as applied to CRC,
and as a potential component of a population-based cancer
screening program. We generated simulated data repre-
senting a typical North American population including a
variety of genetic proﬁles, with a range of relative risks and
prevalences for individual risk genes. We then used these
data to estimate parameters characterizing the predictive
value of a logistic regression model built on genetic
markers for CRC. Meta-analyses of genetic associations
with CRC were used in building science to inform the
simulation work, and to select genetic variants to include in
logistic regression model-building using data from the
ARCTIC study in Ontario, which included 1,200 CRC
cases and a similar number of cancer-free population-based
controls. Our simulations demonstrate that for reasonable
assumptions involving modest relative risks for individual
genetic variants, that substantial predictive power can be
achieved when risk variants are common (e.g., preva-
lence[20%) and data for enough risk variants are avail-
able (e.g., *140–160). Pilot work in population data shows
modest, but statistically signiﬁcant predictive utility for a
small collection of risk variants, smaller in effect than age
and gender alone in predicting an individual’s CRC risk.
Further genotyping and many more samples will be
required, and indeed the discovery of many more risk loci
associated with CRC before the question of the potential
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Introduction
Colorectal cancer (CRC) screening in Canada
CRC is the second leading cause of cancer death in
Canadians, with an estimated 22,000 new cases and 9,100
deaths in 2009 (Canadian Cancer Society Steering Com-
mittee 2009). Although incidence and mortality rates for
CRC in Canada are among the highest in the world, a very
low proportion of the population undergoes screening for
this form of cancer (Rabeneck and Paszat 2004). In fact,
more men undergo prostate cancer screening than CRC
screening, whereas the weight of evidence as to efﬁcacy
and effectiveness is greater for the latter (Sirovich et al.
2003). Recommendations put forward in 2002 by the
Canadian National Committee on Colorectal Cancer
Screening to introduce population-based fecal occult blood
(FOB) screening of average risk individuals 50 years and
older (National Committee on Colorectal Cancer Screening
2002) are now being implemented in several Canadian
provinces. However, there are concerns about the likely
population impact of FOB screening. First, considerable
variation (46–92%) in the sensitivity of FOB screening has
been reported (Hewitson et al. 2007), leading to uncertainty
about the extent to which the ﬁndings of the RCTs will
translate into screening outcomes in practice, although
recent advances in immunochemical-based FOB testing
suggests the latest FOB assays will detect 60–94% of
cancers and 20–67% of advanced neoplasia (Allison et al.
2007). Second, it has been suggested that about a quarter of
the decrease in colorectal mortality attributable to FOB
screening reported in the Funen and Nottingham trials may
have been due to better disease awareness on the part of
patients who developed interval CRC who had been
assigned to receive screening, and therefore that the
reduction in CRC mortality attributed to FOB screening
had been over-estimated (Autier et al. 2003). Third, a
recent review casts doubt on the overall efﬁcacy of FOB
screening in prolonging the lives of those who are
screened, on the basis of an examination of all-cause
mortality in data from the 2000 Cochrane review
(Moayyedi and Achkar 2006). Evidence on the effective-
ness of screening modalities other than FOB testing is
limited. Case–control and cohort studies suggest that
screening by sigmoidoscopy reduces incidence and mor-
tality due to distal CRC, but randomized-control trial
(RCT) evidence is not available (UK Trial of Early
Detection of Breast Cancer Group 1988; Selby et al. 1992;
Newcomb et al. 1992;M u ¨ller and Sonnenberg 1995).
Participation rates may be similar to FOB screening
(Bampton et al. 2000; UK Flexible Sigmoidoscopy
Screening Trial Investigators 2002), or lower (Multicentre
Australian Colorectal-neoplasia Screening (MACS) Group
2006. For colonoscopy screening, it is not clear that any
potential gain in beneﬁt compared with ﬂexible sigmoid-
oscopy screening outweighs the higher risk of perforation
and complications associated with the use of sedatives,
particularly if this form of screening is repeated over time;
participation rates are lower for colonoscopy than sig-
moidoscopy-based programs (Rex et al. 1997; Simon 2000;
Bampton et al. 2000; Atkin 2003), and there is concern
about the capacity of the Canadian health system to provide
greater access to colonoscopy-based screening (Schabas
2003).
Potential utility of genomic information in CRC
screening
Given that about 30% of the risk of CRC is attributable to
heritable factors (Lichtenstein et al. 2000), and less than
5% to high penetrance variants (Aaltonen et al. 2007), the
balance of the genetic risk is likely explained by numerous
low penetrance variants, many of which may be common.
It is well established that genetic testing for low penetrance
alleles one at a time is not useful in a screening or diag-
nostic context (Vineis et al. 2001; Khoury et al. 2004;
Madlensky et al. 2005; Janssens et al. 2008) and may even
cause unintended psychosocial harm. However, because a
moderate number of common, low penetrance variants, in
combination, may account for a substantial proportion of
the disease (Yang et al. 2003; Khoury et al. 2004; Yang
et al. 2005), it seems reasonable to postulate that infor-
mation on a combination of genetic variants may be useful
in screening. There are several ways in which inclusion of
an adjunctive genomic screening proﬁle might improve
population screening for CRC. First, genomic information
might be useful in triaging individuals to different types
and intensities of screening. Second, it is possible that an
adjunctive proﬁling tool based on genomic information
might increase the uptake of existing screening methods.
For example, population-based studies have shown that the
likelihood of participating in CRC screening is positively
associated with having a family history of the disease
(Slattery et al. 2000, 2004; Mandelson et al. 2000;
Madlensky et al. 2003; Ramji et al. 2005). In a study of
patient and physician preferences for various types of tests
to detect CRC, both patients and physicians stated that they
considered accuracy as the most important feature in
deciding on which test they would choose; thus, improved
efﬁcacy through an adjunctive test might also lead to
higher uptake (Ling et al. 2001). Third, since the magni-
tude of the effect of population-based cancer screening on
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123cancer-speciﬁc mortality depends on the extent of repeated
compliance (Gertig et al. 1998; Kronborg et al. 2004), it is
possible that inclusion of an adjunctive proﬁle at the initial
screening might help identify, and target effort towards,
those at greatest need of repeated screening. Finally,
genomic information may assist in decisions about pre-
ventive interventions or subsequent screening modality or
intensity in individuals after the result of the ﬁrst screening
test is known and any related interventions have been
carried out. For example, genomic information could assist
in decisions about subsequent management (including
surveillance) of individuals in whom polyps were detected
(Ransohoff 2002).
Evidence for the potential value of genomic
information in CRC risk proﬁling
Although a substantial proportion of candidate gene studies
of common variants have failed to replicate, a number of
variants have been associated with the risk for CRC (Houl-
ston and Tomlinson 2001; de Jong et al. 2002; Chapelle
2004; Kemp et al. 2004; Sharp and Little 2004; Chen et al.
2005;LittleandSharp2007).Inaddition,recentresultsfrom
a number of genome-wide association (GWA) studies have
implicated at least ten loci as being associated with CRC
(Broderick et al. 2007; Tomlinson et al. 2007, 2008; Houl-
ston et al. 2008; Jaeger et al. 2008; Tenesa et al. 2008).
Combining the information for robust candidate gene asso-
ciationsandGWAstudiesmaynotonlyexplainasubstantial
share of the as yet unexplained genetic component of CRC
etiology, but may also shed light on the pathways and
mechanisms at play. Previous authors have published sim-
ulationstudieslookingatthenumberofhypotheticallowrisk
variants that would be necessary to achieve various bench-
marks of population attributable risk and predictive utility
(Yang et al. 2003, 2005; Janssens et al. 2007). What is
unclear is how such a genetic test might perform as an
adjunct to established CRC screening modalities such as
FOB testing, colonoscopy and sigmoidoscopy.
Aims of our study
In this paper we evaluate a hypothetical genetic test
including increasing numbers of simulated genetic variants,
and evaluate the degree to which such tests might be useful
in enhancing the efﬁcacy of established screening modal-
ities. Particularly, we have focused on a very low relative
risk range given that the most recently characterized risk
variants from GWA studies have typically had marginal
relative risks in the range of 1.1–1.3. In addition, we
develop risk prediction models in population-based case–
control data from the ARCTIC study (Zanke et al. 2007)t o
evaluate the utility and predictive value of available
genomic information from an already completed study of
risk factors for CRC. The variants chosen for inclusion in
risk prediction models were informed by an extensive lit-
erature review of genetic risk factors for CRC completed
by the authors (Campbell et al. 2009).
Methods
Statistical methods: simulation studies
For all simulations, a simple genetic model was assumed,
whereby the risk allele was either present or absent for each
of multiple loci. Using this approach, the risk status for
each individual could be simulated using a binomial
distribution with n = number of genes, x = number of
genes with the risk allele, and p = prevalence of risk
genotype for each individual gene such that,
pðxÞ¼ n
x

pxð1   pÞ
ðn xÞ:
This binomial distribution was used to create a table of
probabilities and combined odds ratios for genotypes with
increasingnumbersofriskvariantsfrom0ton,thenumberof
genes speciﬁed in the simulation scenario. From this table, a
simulated population was generated whereby the genotype
for each individual was assigned based on a random draw
from a uniform [0, 1] distribution. The odds ratio corre-
sponding to the assigned genotype was calculated by expo-
nentiatingtheperalleleoddsratioaccordingtothenumberof
riskalleles.Thiscorrespondstoanadditive(onthelogscale)
risk model. Although clearly important, we ignored the
potential effects of gene–gene and gene–environment
interactions in our simulations. We assumed that risk vari-
ants were either present or absent, and conferred the stated
risk independent of the presence or absence of other genetic
or environmental effects. Although multiplicative effects
may be important in multi-locus genetic effects, we chose to
reportonthemoreconservativeadditivemodelthatassumes
no synergy among risk loci.Allsimulations were carriedout
in the R statistical package. Inputs to the simulation were
based on existing empirical evidence. We used odds ratio
estimates of 1.1–1.5 to demonstrate the range of possible
outcomes for a variety of scenarios, but we focus on odds
ratio = 1.2 and prevalence of 20% because these values are
consistent with recent GWA ﬁndings for CRC and several
other chronic diseases.
Genetic variance
Under the polygenic model, the distribution of risk
approximately follows a lognormal distribution, thus
Hum Genet (2010) 128:89–101 91
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2). The relative risk of disease in
monozygous twins (which we denote kmonozygotic) and
dizygotous twins/siblings (which we denote ksibling) are
related to each other, and to the genetic variance (i.e.,
variance of the polygenic risk model on the log scale) by
equation: kmonozygotic ¼ k
2
sibling ¼ er2
(Pharoah et al. 2002,
2008). Previous studies have reported estimates in the
range of 2–4 for ksibling for common cancers including
breast and colorectal (Pharoah et al. 2002, 2008; Lichten-
stein et al. 2000; Ahlbom 1997), hence we have conser-
vatively assumed a ksibling = 2, which corresponds to a
standard deviation of 1.2 for the polygenic lognormal risk
model (Pharoah et al. 2002, 2008). Based on the above
assertions, we have used SD = 1.2 to deﬁne the ceiling at
which all of the hereditary variance has been explained in
our simulation work.
Sensitivity, speciﬁcity and area under the ROC curve
(AUC)
Receiver operator characteristic (ROC) curves which plot
sensitivity versus (1-speciﬁcity) were used in assessing the
performance of our ﬁtted logistic regression models
(Hanley and McNeil 1982). Areas under the ROC curve
(AUC) were estimated using the concordance index sta-
tistic c (Harrell et al. 1982). The c-statistic was calculated
using the somers2 function from the Hmisc package in R
(Harrell et al., http://cran.rproject.org/web/packages/).
Sensitivity, speciﬁcity, positive and negative predictive
values were also reported, requiring that a cutoff be spec-
iﬁed as a classiﬁcation rule. An effective screening test
generally has a very high sensitivity (i.e., identiﬁes a high
proportion of disease cases) with the trade-off of accepting
a certain proportion of false-positives. Our objective is not
the development of a stand-alone screening tool, but rather
an adjunctive test, to enrich the screening pool for con-
ventional screening methods. Hence, we have focused on
maximizing AUC, and have chosen a somewhat naı ¨ve
cutoff, such that the sum of sensitivity and speciﬁcity is
maximized, and in the results we report the sensitivity,
speciﬁcity, and positive predictive value at this cutpoint.
As another measure of predictive power, we also calculated
the proportion of CRC cases that would be captured in the
top 50% of ranked risk scores. If the test was used to
calculate a risk score for a large number of individuals, and
these scores were ranked from highest to lowest, then the
top 50% based on rank were selected as positive tests. This
is another somewhat arbitrary rule; however, screening is
currently recommended in 100% of individuals over the
age of 50 in North America, so our aim is to illustrate the
properties of an adjunctive test that could focus effort on
the half of the population at the highest genetic risk. A test
that provides no more predictive ability than a coin toss
will capture about 50% of cases in the top 50% of ranked
risk scores. A highly predictive test will capture much
more than 50% of cases thus creating an enriched screening
pool. We proposed as a benchmark, a test that could cap-
ture 80% of all future CRC cases in the top 50% of ranked
test scores. Such a test would enrich the screening pool
enough to be useful as an adjunctive screening test.
Empirical conﬁdence intervals
In order to estimate directly the variance associated with
each of our statistics of interest, we repeated the Monte
Carlo approach used to generate the simulated populations
500 times. Using these 500 samples of size of 100,000
each, we calculated all of the statistics of interest described
above for each sample. We calculated point estimates using
the median of the 500 estimates, and calculated non-para-
metric 95% conﬁdence intervals by ranking the point
estimates from the 500 samples and computing the 2.5th
and 97.5th percentiles. This approach does not require
distributional assumptions (e.g., normality) and the conﬁ-
dence limits are not constrained to be symmetrical. This
allows the generation of more representative plausible
ranges for each statistic of interest.
Simulating the impact of varying scenarios on screening
We simulated the impact of increasing predictive power for
an adjunctive screening test on enrichment of the screening
pool. For example, a genetic test that could capture 80% of
subjects will develop CRC within their lifetime, within the
top 50% of ranked scores of those tested would allow
screening to be focused on those at the highest genetic risk
of disease. Ten-year age-speciﬁc cancer incidence rates and
population structure data were obtained from National
Cancer Institute of Canada data (Canadian Cancer Society
Steering Committee 2009), and Statistics Canada 2006
Census data (Statistics Canada 2006), respectively. We
also simulated the effect of increasing levels of screening
compliance concomitantly with the enriching of the
screening pool. Simulations were carried out varying the
degree of enrichment of the screening pool from 50%
(no enrichment) up to 90% of CRC cases being captured in
the top 50% of scores in the genetic test. For illustrative
purposes, it was assumed that resources were limited for
conventional screening and that 1,000,000 conventional
screening tests were to be performed. Therefore, if
2,000,000 genetic tests were administered then the top
1,000,000 scores (or any other arbitrary cutoff) could be
ﬂagged as candidates for conventional screening. We
classiﬁed simulated subjects into 10-year age and sex risk
groups and estimated the number of subjects who would
develop CRC in the next 10-year window, who would be
92 Hum Genet (2010) 128:89–101
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predictive power, screening compliance and age and sex
categories. We calculated these numbers ﬁrst within age
and sex subgroups, and then a weighted overall average
based on Canadian population structure.
Statistical methods: analyses in a population-based
case–control study of CRC, the Assessment of Risk
for Colorectal Tumors in Canada (ARCTIC) Study
Multivariate modeling was carried out using available case
control data and genotyping from the Assessment of Risk
for Colorectal Tumors in Canada (ARCTIC) Study. The
ARCTIC case–control study has been described in detail
elsewhere (Zanke et al. 2007). Brieﬂy, the ARCTIC study
involved 1,257 CRC cases and 1,336 matched community
controls from the Ontario Familial Colorectal Cancer
Registry. Cases with known germline APC, MSH2, MLH1,
MSH6 or biallelic MUTYH mutations were excluded.
Extensive genotyping was performed for each subject,
including several large genotyping arrays involving mark-
ers for over 600,000 single nucleotide polymorphisms
(SNPs). Through a meta-analysis and systematic review,
we identiﬁed an extensive list of polymorphisms which had
been studied in relation to CRC (Campbell et al. 2009).
Using the results of this review as a starting point, we
selected about 80 polymorphisms, spanning over 30 genes
and nearly all chromosomes. These variants were selected
for inclusion based on the strength of association, consis-
tency and quality of the evidence and validation of ﬁnd-
ings. These included genetic polymorphisms affecting
xenobiotic metabolism (GSTM1, GSTT1, GSTA1, NAT1,
NAT2); related to folate and one-carbon metabolism
(MTHFR, MTRR, MTR); associated with alcohol metabo-
lism (ADH1C, CYP2E1); inﬂuencing iron metabolism
(HFE); identiﬁed via GWA studies [8q24, 8q23.3 (EIFH),
10p14, 11q23, 15q13, 18q21(SMAD7), 14q22(BMP4),
16q22(CDH1),19q13(RHPN2), and 20p12]; inﬂuencing
vitamin D and calcium metabolism (VDR); inﬂuencing
lipid or insulin metabolism (APOE, IRS1), affecting
inﬂammation and immune response (HRAS1, IGF1, IL6,
IL8, PPARG, TNF-a, PTGS1), tumor growth factors
(TGFBR1, CCND1, CDH1), and highly penetrant variants
with large effects (APC, MLH1, MLH3, MSH2). To address
missing values for SNP covariates in multivariate model-
ing, we imputed missing genotypes using the haplotype
clustering method implemented in the open-source soft-
ware BEAGLE (Browning and Browning 2007). Genotype
frequencies for each bi-allelic genotype were compared to
that expected to arise from random mating. A v
2 test was
used to test whether any departures from HWE were more
extreme than would be expected by chance (Thomas 2004).
Multivariate logistic regression analyses and model
validation procedures were carried out in SAS version 9.1
(SAS Institute, Cary, NC) and R version 2.9 (The R
Foundation for Statistical Computing, Vienna, Austria).
Results
Genomic proﬁling simulations
In Table 1, the results for selected simulations are pre-
sented, for 20–400 putative risk alleles. For simulations
with 20 putative genes, odds ratio of 1.2 for each risk
variant, and risk variant prevalence of 20%, AUC was
59.2% and 61.8% of cases were captured in the top 50%
of ranked risk scores (abbreviated as CCNT for case
concentration). At the maximum observed sensitivity ?
speciﬁcity, sensitivity was 49.5%, speciﬁcity was 63.9%
and positive and negative predictive values were 9.3 and
94.4%, respectively. Hence, only 9 out of every 100
positive tests were true positives under this prediction
model. If a test threshold was selected such that
CCNT = 0.80, then for the same allele frequency and
average relative risk, roughly 140–160 risk variants would
be required. At this level, positive predictive value is still
only about 13%. Hence even with a highly predictive test,
where 80% of cases are being captured in the ‘‘test
positive’’ pool, 87 out of every 100 positive tests are
false-positives. We also ran simulations to evaluate the
relative contribution of a small number of rare variants
with higher penetrance, with varying prevalence and odds
ratios. For example, from Table 1, with 20 risk variants,
odds ratios of 1.2 per variant, and risk variant prevalence
of 20%, AUC is 59.2%, and CCNT is 61.8%. Adding the
effect of ﬁve higher risk variants with odds ratios of 20
per variant, and rare prevalence of 0.1%, raises AUC to
0.607, and CCNT to 63.3%. However, adjusting the
parameters such that the ﬁve rare variants have a preva-
lence of 1% but much lower odds ratios of 5.0 per rare
variant leads to an AUC of 0.64, and CCNT of 66.3%.
These results are compatible with the view that a col-
lection of common low penetrance variants could together
explain a much larger proportion of the genetic variance
than a small number of rare variants with extremely high
relative risks. However, a substantial number of such
variants would be necessary. Figure 1 summarizes results
for the simulations for numbers of risk alleles ranging
from 20 to 400 risk variants, for odds ratios of 1.1–1.5.
The plot of number of risk variants versus CCNT in
Fig. 1 suggests that with average relative risk of 1.2, at
least 140–160 risk alleles would be required for the
combined genomic information to really be useful in a
screening or risk triage setting, based on the benchmark
of requiring a test to be able to correctly identify 80% of
Hum Genet (2010) 128:89–101 93
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(horizontal reference line denotes this benchmark). To
reach the upper limit of genetic variance (explaining all
possible hereditary CRC) would require in excess of 300
risk alleles (horizontal reference line of SD = 1.2 in
Fig. 2). At this threshold, close to 90% of cases would be
contained in the top 50% (CCNT[87.3%).
Application of simulated genomic proﬁles
in the context of population screening
Table 2 shows the number of cases of cancer that would
be screened within varying test predictive power, and
compliance levels. These are expressed as CRC cases
per 1,000,000 subjects counseled to participate in FOB/
Table 1 Simulation results for 20–400 risk alleles: statistics and empirical conﬁdence intervals
Simulation no. 1234
Number of loci 20 40 60 80
AUC 0.592 (0.585, 1.598) 0.629 (0.622, 0.636) 0.656 (0.649, 0.663) 0.678 (0.672, 0.685)
CCNT 0.618 (0.607, 0.629) 0.666 (0.654, 0.677) 0.700 (0.690, 0.711) 0.728 (0.718, 0.739)
SD 0.302 (0.301, 0.303) 0.428 (0.426, 0.429) 0.524 (0.522, 0.526) 0.605 (0.602, 0.607)
Sensitivity 0.495 (0.484, 0.609) 0.582 (0.569, 0.593) 0.633 (0.512, 0.645) 0.662 (0.560, 0.683)
Speciﬁcity 0.639 (0.523, 0.642) 0.606 (0.603, 0.610) 0.592 (0.589, 0.710) 0.587 (0.582, 0.691)
PPV 0.093 (0.088, 0.096) 0.100 (0.097, 0.103) 0.105 (0.102, 0.118) 0.111 (0.106, 0.124)
NPV 0.944 (0.942, 0.948) 0.950 (0.949, 0.952) 0.955 (0.951, 0.957) 0.958 (0.954, 0.961)
Simulation no. 5678
Number of loci 100 120 140 160
AUC 0.697 (0.690, 0.702) 0.713 (0.707, 0.719) 0.727 (0.721, 0.733) 0.740 (0.734, 0.746)
CCNT 0.750 (0.740, 0.760) 0.770 (0.761, 0.780) 0.787 (0.778, 0.796) 0.802 (0.792, 0.810)
SD 0.676 (0.674, 0.679) 0.741 (0.738, 0.744) 0.801 (0.797, 0.804) 0.856 (0.852, 0.860)
Sensitivity 0.613 (0.602, 0.709) 0.648 (0.635, 0.661) 0.677 (0.598, 0.689) 0.700 (0.624, 0.714)
Speciﬁcity 0.674 (0.578, 0.677) 0.663 (0.659, 0.667) 0.655 (0.652, 0.730) 0.649 (0.645, 0.721)
PPV 0.123 (0.110, 0.127) 0.126 (0.122, 0.131) 0.129 (0.125, 0.145) 0.132 (0.128, 0.147)
NPV 0.962 (0.960, 0.963) 0.964 (0.960, 0.966) 0.966 (0.962, 0.968) 0.966 (0.964, 0.970)
Simulation no. 9 10 11 12
Number of loci 180 200 250 300
AUC 0.751 (0.746, 0.757) 0.762 (0.756, 0.767) 0.785 (0.779, 0.790) 0.803 (0.798, 0.808)
CCNT 0.815 (0.806, 0.824) 0.827 (0.819, 0.836) 0.853 (0.844, 0.860) 0.873 (0.866, 0.880)
SD 0.908 (0.905, 0.912) 0.957 (0.953, 0.961) 1.071 (1.066, 1.075) 1.173 (1.169, 1.178)
Sensitivity 0.663 (0.650, 0.732) 0.685 (0.673, 0.748) 0.731 (0.673, 0.743) 0.727 (0.683, 0.776)
Speciﬁcity 0.710 (0.640, 0.713) 0.703 (0.638, 0.706) 0.689 (0.686, 0.745) 0.729 (0.677, 0.775)
PPV 0.146 (0.130, 0.150) 0.148 (0.133, 0.152) 0.152 (0.148, 0.169) 0.168 (0.153, 0.184)
NPV 0.966 (0.964, 0.970) 0.967 (0.966, 0.971) 0.971 (0.968, 0.973) 0.973 (0.970, 0.976)
Simulation no. 13 14
Number of loci 350 400
AUC 0.819 (0.814, 0.823) 0.830 (0.826, 0.835)
CCNT 0.889 (0.882, 0.895) 0.901 (0.895, 0.908)
SD 1.268 (1.263, 1.273) 1.353 (1.348, 1.359)
Sensitivity 0.758 (0.711, 0.771) 0.753 (0.740, 0.756)
Speciﬁcity 0.719 (0.715, 0.765) 0.751 (0.707, 0.755)
PPV 0.171 (0.166, 0.190) 0.185 (0.168, 0.191)
NPV 0.975 (0.972, 0977) 0.976 (0.974, 0.979)
AUC area under receiver–operator curve, CCNT % cases captured in top 50% of ranked model scores, SD standard deviation, PPV positive
predictive value, NPV negative predictive value
SD of the genetic risk distribution: 1.2 is the theoretical threshold where all of the hereditary component of CRC has been explained
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123endoscopy based on being in the top 50% of the
2,000,000 subjects in whom the simulated genetic proﬁle
is evaluated, who then may or may not present themselves
for screening based on the stated compliance rates ranging
from 25 to 100%. Numbers are presented for individual
age groups and then an overall weighted population total
is estimated. For example, for a situation of having an
equivocal genetic test (50/50, no predictive utility), and
25% compliance with conventional screening, 2,746
cancer patients would present themselves for the FOB/
endoscopic screening test. If a strongly predictive proﬁl-
ing test was deployed that concentrated 80% of cases into
the top 50% of the sample, and screening compliance
remained at 25%, 4,398 cancers would be brought into
screening. If, as hypothesized, the screening compliance
of the subjects was to improve to say to 40%, this would
result in 7,039 cancers being brought to screening. Hence,
the combination of a strongly predictive genetic test and
the improved screening compliance leads to an additional
4,293 CRC cases being brought into the screening pool.
The majority of these additional cancers would be
detected by the latest FOB/endoscopic tests. In Table 3,
the impact of a genomic test that captures 80% of cases in
the top 50% of test scores is explored in individual age
and gender categories.
Risk models via logistic regression in ARCTIC
case–control data
Less than one-third of the targeted candidate polymor-
phisms were available for study based on completed
genotyping in ARCTIC data. Univariate analyses of all
available candidate SNPs from ARCTIC study genotyping
data were conducted. Allele frequencies were calculated
and checked for departures from Hardy–Weinberg Equi-
librium (HWE). No serious departures from HWE were
noted. Frequencies and univariate odds ratios were calcu-
lated for each SNP. Odds ratios were calculated for three
contrasts of interest: (1) heterozygotes versus reference
allele homozygotes, (2) variant homozygotes versus ref-
erence allele homozygotes and (3) ‘‘per allele’’ odds ratios
where individuals were scored as 0, 1 or 2 corresponding to
the number of variant alleles they carried. The results of
univariate analyses are reported in Fig. 2. SNPs demon-
strating nominal signiﬁcance in univariate analyses were
included in multivariate modeling procedures. A number of
environmental risk factors were also included in order to
explore relevant gene 9 environment interactions. These
biologically relevant gene–environment interactions were
considered in individual logistic models. SNP–environ-
ment interactions that achieved nominal signiﬁcance
Fig. 1 Simulation results:
20–500 risk alleles and
OR = 1.1–1.5, for area under
the ROC curve (AUC), case
concentration (CCNT) and
genetic risk standard deviation
(SD). #Horizontal reference line
indicates threshold of 80% of
CRC cases being captured in top
50% of ranked test scores.
*Horizontal reference line
indicates theoretical maximum
standard deviation of the genetic
risk distribution (SD) explained
by heritable factors (SD = 1.2)
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123(P\0.10) in individual models were included as candi-
dates in multivariate modeling. Initial models included
only SNPs and SNP 9 SNP interactions. Stepwise variable
selection was used, with P\0.10 the cutoff to enter the
model, and P\0.20 to be removed from the model once
included. Model hierarchy was respected in the modeling
process, meaning in order for an interaction to be included
in the model, both of the main effects were forced into the
model. To address overﬁtting, tenfold cross-validation was
used, and all reported statistics are from cross-validated
models. The ﬁnal model from this procedure included
variants: rs1801282-PPARG P10A, rs2289046-IRS2,
rs2472300-CYP1A2 C-164A tag snp, rs3099844-TNF-
alpha G-308A, rs4779584-CRAC1, rs10505477-ARCTIC
8q24, rs10735810-VDR FokI T[C and interactions:
(rs1801282 9 rs4779584), (rs1801282 9 rs10505477) and
(rs1801282 9 rs10735810). AUC as measured by the
c-statistic (concordance index) was 0.54. Models addi-
tionally including age and gender gave an AUC of 63%. In
contrast, a model with only age and sex gave an AUC of
60%. Stepwise variable selection resulted in a model that
included age, sex, rs1801282, rs2289046, rs2472300,
rs4779584, rs10505477, rs7296651, tertile of red meat
consumption (rmtert), history of colitis (coli), aspirin use
(asp), ibuprofen use (ibp), and interactions: age 9 sex,
Fig. 2 Univariate frequencies and odds ratios for candidate risk
genes in ARCTIC data. MM/mm major/minor allele homozygote, Mm
heterozygote
Table 2 Future cancers potentially screened and detected early out of
1,000,000 triaged screenees based on predictive power of the genetic
proﬁle, and projected increase in screening compliance (weighted by
Canadian population structure from 2006 Canadian Census)
CCNT Compliance rate
a
25 30 40 50 60 100
0.50 2,746 3,297 4,398 5,500 6,599 11,004
0.60 3,297 3,958 5,279 6,599 7,920 13,204
0.70 3,847 4,617 6,157 7,700 9,240 15,405
0.80 4,398 5,279 7,039 8,801 10,561 17,608
0.90 4,949 5,940 7,920 9,901 11,882 19,808
CCNT % of all CRC cases in top 50% of ranked genomic proﬁle
scores
a Compliance refers to the proportion of subjects counseled to
undergo screening who actually attend screening
Table 3 Future cancers potentially screened and detected early for a
genomic proﬁle that detects 80% of cancers in the top 50% of ranked
proﬁle scores in age and sex groups and overall, with the impact of
increasing levels of compliance across columns
Age and sex Compliance rate
a
25 30 40 50 60 100
Male 40–49 133 160 213 267 320 534
Male 50–59 453 544 725 907 1,088 1,814
Male 60–69 712 855 1,140 1,425 1,710 2,851
Male 70–79 730 876 1,168 1,460 1,753 2,921
Male 80–89 313 375 501 626 751 1,253
Female 40–49 137 165 220 275 330 551
Female 50–59 351 421 561 702 842 1,404
Female 60–69 489 586 782 978 1,173 1,956
Female 70–79 628 754 1,005 1,256 1,508 2,513
Female 80–89 452 543 724 905 1,086 1,811
Total 4,398 5,279 7,039 8,801 10,561 17,608
a Compliance refers to the proportion of subjects counseled to
undergo screening who actually attend screening
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123rs1801282 9 rs4779584, rs1801282 9 rs7296651, rs4779
584 9 rs7296651, rs2289046 9 rmtert, rs7296651 9 rmt-
ert and rs2289046 9 asp. The AUC for this model was
0.66. Given that most candidate polymorphisms available
in ARCTIC failed to demonstrate nominal statistical sig-
niﬁcance individually, an aggregate model was constructed
to explore pooled effects of increasing numbers of variant
alleles. All SNPs were re-parameterized so that the refer-
ence allele conferred low risk and the variant allele con-
ferred elevated risk. Considering all 26 variants
collectively by scoring each locus as having 0, 1 or 2 risk
alleles and pooling and grouping the data showed a highly
statistically signiﬁcant trend of increasing risk with
increasing numbers of risk alleles; however, the effect size
was small in magnitude. For every additional risk allele,
risk increased by about 8% [odds ratio 1.08 (95% CI 1.05–
1.11)] (see Fig. 3a). Grouping subjects into quintiles, the
odds ratio for subjects with 27? risk alleles versus 0–21
risk alleles was 1.67 (95% CI 1.28–2.18) (see Fig. 3b).
More detailed grouping demonstrated that subjects with 30
or more variant alleles have an odds ratio of 2.62 (95% CI
1.27–4.04) versus subjects with 20 or fewer (see Fig. 3c).
Although modest in magnitude, the effects showed a strong
and consistent linear trend.
Discussion
We have performed a variety of analyses using both simu-
lated and empirical population data to illustrate how a
genetic proﬁle with moderate predictive power, while not a
viable screening test in isolation, could be an important
tool when employed as an adjunct to conventional CRC
screening modalities such as FOB testing and endoscopy
(colonoscopy/ﬂexible sigmoidoscopy). We developed risk
prediction models in data from the ARCTIC case–control
data using a collection of polymorphisms identiﬁed
through an extensive literature search for risk variants
identiﬁed in genetic association studies (both candidate
gene and GWA). Our list consisted of approximately 80
Fig. 3 a Combining all alleles
into a risk allele score (risk
allele count = 0, 1 or 2 per
locus), maximum of possible 52
alleles for 26 variants. b
Combining all alleles into a risk
allele score (risk allele
count = 0, 1 or 2 per locus),
risk allele count grouped into
quintiles. c Combining all
alleles into a risk allele score
(risk allele count = 0, 1 or 2 per
locus), risk allele counts
grouped into detailed categories
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123polymorphisms, of which less than 30 were available in the
existing ARCTIC data. Model building in this limited
subset led to models with signiﬁcant effects from a statis-
tical perspective, but which failed to demonstrate sufﬁcient
predictive power to be useful. Only a handful of poly-
morphisms reached statistical signiﬁcance individually.
When all the loci were pooled together, subjects with 30 or
more risk alleles had more than a twofold risk increase over
subjects with fewer than 20 risk alleles (OR 2.26 95% CI
1.27–4.04).The odds ratio per additional allele was 1.08
(95% CI 1.05–1.11). Although there have been a number of
risk loci identiﬁed in candidate gene studies, and many
have been replicated in more than one study, only a handful
of these candidate gene effects were replicated in ARCTIC
data. These included variants Cyp1A1 T461N (rs1799814),
VDR Fok1T[C(rs10735810), Cyp1a2 C-164A
(rs2472300 tag SNP) and PPARc P10A (rs1801282). This
is consistent with another recent report that found that very
few positive ﬁndings from previous association studies
could be replicated in a European population (Ku ¨ry et al.
2008). A panel of 52 polymorphisms in 35 genes were
tested in 1,023 patients with sporadic CRC and 1,121
controls from France. The polymorphisms were from
inﬂammation, xenobiotic detoxiﬁcation, one-carbon, insu-
lin signaling, and DNA repair pathways. Logistic regres-
sion was used to model the risk of CRC associated with the
panel of variants both individually in univariate analyses
and in multivariate models. The researchers were able to
replicate the association for only ﬁve of the polymor-
phisms. Three SNPs were shown to increase CRC risk:
PTGS1 C639A, IL8 T-352A, and MTHFR A1298C. Two
other SNPs, PLA2G2A C230T and PPARG C1431T, were
associated with a decrease in CRC risk. Combinations of
risk variants were also identiﬁed that led up to a twofold
increase in risk (OR 1.97, 95% CI 1.31–2.97) (Ku ¨ry et al.
2008). None of the replicated SNPs overlapped with those
replicated in our work thus far, and no other similar
attempts at replicating candidate gene study ﬁndings in
large, independent cohorts have been reported. In another
recently published report, a combined analysis of the
impact of all ten risk loci implicated in GWA studies
together demonstrated a per allele odds ratio of 1.16 (95%
OR 1.13–1.18), and a nearly tenfold increased risk for
subjects with C15 risk alleles versus subjects with B4 risk
alleles (Houlston et al. 2008). When combined, the
cumulative ﬁndings from replicated candidate gene studies
could signiﬁcantly compliment the accruing evidence from
GWA studies to eventually comprise a useful risk model if
all the variants could be measured on a single, easy to
collect and analyze genomic panel. In our simulation work
we attempted to extrapolate from the ﬁndings in population
data to look at the hypothetical impact of an expanded
genomic risk proﬁle. For models including a plausible
number of risk variants with risk allele frequency of
approximately 20% and odds ratios in 1.1–1.5 range, it is
possible to achieve meaningful predictive power and sub-
stantial population attributable fraction (PAF). Our results
suggest it would take at least 300 independent risk alleles
to explain all of the genetic component of CRC, and
between 140 and 160 risk alleles to provide a genomic
proﬁle that could capture 80% of future cancers in the 50%
of subjects at highest genetic risk. Similar reports have
been published for other common cancers. A recent study
estimates that given current knowledge of breast cancer
susceptibility loci, the half of the population at highest
genetic risk based on current knowledge, account for 60%
of all cases of breast cancer (Pharoah et al. 2008).
Estimates that give current knowledge of breast cancer
susceptibility loci, the half of the population at highest
genetic risk based on current knowledge, account for 60%
of all cases of breast cancer. If all possible susceptibility
loci were known, they estimate that the top 50% of the
population in terms of genetic risk would represent about
88% of breast cancer cases. These estimates are consistent
with those reported in similar investigations of the hered-
itary component of risk for sporadic CRC.
Despite the fact that germline genomic proﬁling in
disease prevention has not as yet been adequately assessed
(Janssens et al. 2004; Khoury et al. 2004; Yang et al. 2003),
several companies have begun offering personalized
genomic testing that includes a very small number of
variants identiﬁed mostly in GWA studies that have shown
association with CRC among other diseases. Some go as
far as to provide a composite risk score based on the cli-
ents’ genotypes at these loci. The variants included in these
tests are often not supported by adequate evidence (i.e.,
systematic review, meta-analysis repeated replication of
ﬁndings) (Caulﬁeld et al. 2001; Human Genetics Com-
mision, UK 2003; Gollust et al. 2003; Gray and Olopade
2003; Williams-Jones 2003; American College of Medi-
cine Genetics. Board of Directors 2004; McCabe and
McCabe 2004; Kutz 2006; Janssens et al., 2008).
The trajectory and rate of discovery of novel risk loci in
GWA studies and meta-analysis of GWAs suggest it is
possible that within a few years enough risk alleles will
have been characterized to allow the formulation of a
useful genomic proﬁle. However, at some point, there will
inevitably be diminished returns with regard to the mag-
nitude of effect sizes for novel risk loci. In the near future,
while the coverage of the genome is still improving, it is
possible that newly discovered risk variants will be com-
parable in effect size to those described before. However,
once all of the overt risk loci have been described, then
new alleles will only be detected through the increased
power inherent in pooled analysis of multiple GWA studies
or larger studies conducted via investigator networks.
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123So, some argue it is inevitable that the relative risk for
newly described loci will trend consistently downward
(Goldstein 2009). Should the per-allele relative risk keep
dropping well below 1.1, this will hamper the likelihood of
a useful predictive model emerging that includes exclu-
sively genomic factors. There are a number of established
non-genetic risk factors that could easily be incorporated
into future genomic proﬁles. Robust gene–gene and gene–
environment interactions could also contribute valuable
information as they become better characterized. Hence,
the evolution of genomic proﬁling need not be limited to
inclusion of solely genetic risk factors.
Assuminganadequatenumberofallelesareidentiﬁedand
have sufﬁcient effect size, our simulations have demon-
strated that a predictive genetic model as an adjunct test
withinapopulationscreeningprogramcouldpotentiallylead
to better targeting of screening services to those at highest
risk, and better adherence in those to whom screening is
recommended. Overﬁttingisanissuethatmustbeaddressed
in building predictive models to be used to risk-stratify new
individuals—models need to be appropriately validated and
calibratedtoaccountforthismodeluncertainty.Muchlarger
samples are required to detect small effects—especially for
interactions, and multivariate modeling. Although our
motivating example has been CRC, our results could easily
be extended to other chronic diseases with a hereditary
component. Indeed, future directions will undoubtedly
involve a genetic proﬁle that encompasses a spectrum of
diseases. In many cases, the most important genetic variants
act in the etiology of more than one disease. Although more
low penetrance risk alleles will need to be identiﬁed before
genomicinformationcanbeutilizedinanimpactfulway,our
results provide evidence that the concept is promising given
a reasonable and realistic set of conditions. Although the
ARCTIC study was well powered to look at associations
betweencommonSNPSandCRC,powerdiminishesrapidly
for evaluation of gene–environment and gene–gene inter-
actions, as well as for polymorphisms with much smaller
minor allele frequencies, and investigations in subgroups of
interest. Pooled analysis among several large CRC case–
control studies would allow for a much more powerful sta-
tistical evaluation of these questions. This will be facilitated
via existing networks of investigators (e.g., HUGEnet) and
existing research collaborations.
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